Health care industry
Clinical trials evaluating the combination of Vidaza(R) (azacitidine for injectable suspension) with histone deacetylase (HDAC) inhibitors have shown promising results in the treatment of higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Three studies presented at the 48th Annual Meeting and Exposition of the American Society of Hematology
Drugs
Merck KGaA, a pharmaceutical company, has recently entered into an agreement with Glenmark Pharmaceuticals for the development and commercialization of Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes. Separately, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved Gardasil,
Drugs
Researchers at Memorial Sloan-Kettering Cancer Center in New York City, U.S., have made significant discoveries in the field of cancer treatment. Studies conducted by the center's scientists have shed light on new approaches to understanding and combating various types of cancer. Key Takeaways: * Serum interleukin-12:interleukin-6 ratio
Health care industry
A large-scale international study has found that Xeloda, an oral chemotherapy medication, is as effective as a standard treatment combination in delaying disease progression in patients with advanced colorectal cancer. Roche, the manufacturer of Xeloda, plans to submit the data to worldwide regulatory authorities to seek approval for the treatment.
Drugs
Researchers at Princess Margaret Hospital, Toronto, Canada have made significant contributions to the understanding and treatment of various forms of cancer. A recent study published in Clinical Cancer Research explored the intratumor heterogeneity in gene expression profiles from patients with cervical cancer. The study used gene expression profiling to identify
Drugs
Ohio State University researchers have made significant discoveries in cancer treatment, DNA repair, and heart failure. According to recent studies, cancer treatment with interleukin (IL)-2 therapy yields a 10% to 20% response rate in patients with metastatic melanoma or renal cell carcinoma. Additionally, DNA repair genes XPB and XPD
Cancer treatment
A recent study has reported on the use of a nonreplicating adenoviral vector (Ad5) that contains the wild-type p53 transgene combined with chemotherapy as a novel gene-therapy approach for primary breast cancer. The study, led by M. Cristo-Fanilli and colleagues at the University of Texas, involved 13 patients with locally
Cancer treatment
Breast cancer progression is highly dependent on the growth and development of new blood vessels and lymphatic vessels, a process known as angiogenesis and lymphangiogenesis, respectively. Recent research has identified a key protein, hypoxia-inducible factor 1 alpha (HIF-1 alpha), as a crucial regulator of this process. HIF-1 alpha is a
Cancer treatment
OSI Pharmaceuticals, Inc. has started a Phase III clinical trial of Tarceva (erlotinib) as a targeted adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer (NSCLC) with EGFR-positive tumors. This study aims to evaluate the effectiveness of adjuvant therapy with Tarceva in prolonging disease-free survival in
Cancer treatment
The US National Cancer Institute and the US National Human Genome Research Institute, both part of the US National Institutes of Health, have selected the International Genomics Consortium and the Translational Genomics Research Institute to lead the Human Cancer Biospecimen Core Resource component of The Cancer Genome Atlas pilot project.
Cancer research
Women with type 2 diabetes may face a slightly higher risk of breast cancer due to chronic exposure to insulin resistance and/or hyperinsulinemia. Researchers from Canada conducted a study to compare the incidence of breast cancer in postmenopausal women with and without diabetes. The study, which spanned over 2.
Cancer research
EntreMed, a clinical-stage pharmaceutical company, has started a multi-center Phase 2 study with its lead drug candidate, Panzem NCD, in patients with hormone-refractory prostate cancer (HRPC). The study will be conducted by the University of Wisconsin Comprehensive Cancer Center, with additional sites joining during the third quarter. Dr. Glenn Liu
